Ligand Pharmaceuticals Inc (NAS:LGND)

$ 122.55 -1.78 (-1.43%) Market Cap: 2.32 Bil Enterprise Value: 2.10 Bil PE Ratio: 48.82 PB Ratio: 2.73 GF Score: 75/100

Q3 2024 Ligand Pharmaceuticals Inc Earnings Call Transcript
Nov 07, 2024

$129.9 (+11.12%)

Earnings
Q2 2024 Ligand Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2024

$99.04 (+0.93%)

Earnings
Q1 2024 Ligand Pharmaceuticals Inc Earnings Call Transcript
May 07, 2024

$73.22 (+0.54%)

Earnings
Q4 2023 Ligand Pharmaceuticals Inc Earnings Call Transcript
Feb 27, 2024

$89.2 (+19.86%)

Earnings
Ligand Pharmaceuticals Inc To Host Investor Day Transcript
Dec 12, 2023
Q3 2023 Ligand Pharmaceuticals Inc Earnings Call Transcript
Nov 08, 2023

$52.23 (-1.75%)

Earnings
Q2 2023 Ligand Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2023

$67.13 (+1.25%)

Earnings
Q1 2023 Ligand Pharmaceuticals Inc Earnings Call Transcript
May 04, 2023

$76.71 (+1.70%)

Earnings
Q4 2022 Ligand Pharmaceuticals Inc Earnings Call Transcript
Feb 22, 2023

$72.12 (+1.75%)

Earnings
Ligand Pharmaceuticals Inc Investor and Analyst Day Transcript
Dec 13, 2022
Q3 2022 Ligand Pharmaceuticals Inc Earnings Call Transcript
Nov 07, 2022

$62.84 (+1.35%)

Earnings
Q2 2022 Ligand Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2022

$61.89 (+2.18%)

Earnings
Ligand Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 10, 2022
Q1 2022 Ligand Pharmaceuticals Inc Earnings Call Transcript
May 04, 2022

$59.86 (+2.77%)

Earnings
Q4 2021 Ligand Pharmaceuticals Inc Earnings Call Transcript
Feb 17, 2022

$69.97 (-8.43%)

Earnings
Q3 2021 Ligand Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2021

$94.71 (-1.26%)

Earnings
Q2 2021 Ligand Pharmaceuticals Inc Earnings Call Transcript
Jul 29, 2021

$74.18 (-3.64%)

Earnings
Ligand Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 04, 2021
Q1 2021 Ligand Pharmaceuticals Inc Earnings Call Transcript
May 03, 2021

$90.56 (-0.45%)

Earnings
Q4 2020 Ligand Pharmaceuticals Inc Earnings Call Transcript
Feb 03, 2021

$110.68 (+0.24%)

Earnings
Ligand Pharmaceuticals Inc Extraordinary Shareholders Meeting Transcript
Dec 15, 2020
Q3 2020 Ligand Pharmaceuticals Inc Earnings Call Transcript
Oct 30, 2020

$51.41 (-0.75%)

Earnings
Ligand Pharmaceuticals Inc Virtual Investor Day Transcript
Oct 20, 2020
Q2 2020 Ligand Pharmaceuticals Inc Earnings Call Transcript
Aug 03, 2020

$74.25 (+1.62%)

Earnings
Ligand Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 10, 2020
Q1 2020 Ligand Pharmaceuticals Inc Earnings Call Transcript
May 06, 2020

$63.29 (+1.61%)

Earnings
Ligand Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 10, 2020
Q4 2019 Ligand Pharmaceuticals Inc Earnings Call Transcript
Feb 06, 2020

$57.67 (+0.31%)

Earnings
Q3 2019 Ligand Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2019

$69.67 (+1.27%)

Earnings
Q2 2019 Ligand Pharmaceuticals Inc Earnings Call Transcript
Jul 30, 2019

$59.38 (-11.38%)

Earnings
Q1 2019 Ligand Pharmaceuticals Inc Earnings Call Transcript
May 02, 2019

$79.26 (+1.10%)

Earnings
Ligand Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 13, 2019
Ligand Pharmaceuticals Inc Analyst Day Transcript
Mar 12, 2019
Ligand Pharmaceuticals Inc Announce Sale of Promacta Assets and Royalty to Royalty Pharma Call Transcript
Mar 05, 2019
Q4 2018 Ligand Pharmaceuticals Inc Earnings Call Transcript
Feb 07, 2019

$72.66 (-0.95%)

Earnings

Q2 2019 Ligand Pharmaceuticals Inc Earnings Call Transcript

Jul 30, 2019 / 01:00PM GMT

Release Date Price: $59.38 (-11.38%)

Transcript 10-Q8-K

Operator

Hello and welcome to the Ligand Pharmaceuticals Second Quarter 2019 Earnings Call. (Operator Instructions). And today's call is being recorded. (Operator Instructions). It is now my pleasure to turn today's program over to Todd Pettingill, Senior Director, Corporate Development and Investor Relations. Sir, you may begin.

Todd Pettingill

Ligand Pharmaceuticals Incorporated - Director of Corporate Development

Welcome to Ligand's second quarter of 2019 financial results and business update conference call. Speaking today for Ligand are John Higgins, CEO; Matt Foehr, COO; and Matt Korenberg, CFO.

As a reminder, today's call will contain forward-looking statements within the meaning of federal securities laws. These may include, but are not limited to, statements regarding intent, belief or current expectations of the company and its management regarding its internal and partnered program. These statements involve risks and uncertainties, and actual events or results may differ materially from the projections described in today's press release in this

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.